Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy

Civil Hospices of Lyon

Status: Completed

Conditions: Hepatitis C

Treatments: Other: Triple therapy

Study type: Observational

Funder types: Other

Identifiers

NCT02877199

69HCL16_0552

Details and patient eligibility

About

The hypothesis was to check whether baseline anti-E1E2 antibodies were correlated with the on-treatment viral kinetics and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving protease inhibitor-based triple therapy.

Enrollment: 19 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HCV patients with compensated cirrhosis (Child-Pugh A)
• HCV genotype 1
• non-responders to a previous course of interferon (IFN)/ribavirin
• receiving boceprevir or telaprevir

Exclusion criteria

Trial design

19 participants in 1 patient group

HCV triple therapy

Description:

Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy

Treatment:

Other: Triple therapy